FINANCIAL RESULTS Q3:2024 SLIDE SUPPLEMENT Nasdaq: TKNO November 7, 2024 Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to Teknova's anticipated total revenue, including our expectations for 2024 revenue and free cash ...

Revenue Performance - Total revenue for Q3 2024 was $9.6 million, a 17% increase from $8.2 million in Q3 2023[4] - Clinical Solutions revenue surged 229% to $2.0 million in Q3 2024, compared to $0.6 million in Q3 2023[6] - Teknova reaffirms its 2024 revenue guidance of $35 million to $38 million, anticipating roughly 2% growth in Lab Essentials[11][12] Profitability and Margins - Gross margin for Q3 2024 was 0.9%, significantly down from 18.0% in Q3 2023, primarily due to a $2.8 million non-recurring charge[7] - Net loss for Q3 2024 was $7.6 million, or negative $0.15 per diluted share, an improvement from a net loss of $10.2 million, or negative $0.34 per diluted share, in Q3 2023[9][25] - Adjusted EBITDA for Q3 2024 was negative $5.0 million, an improvement from negative $5.5 million in Q3 2023[10] Cash Flow and Liquidity - The company lowered its 2024 total free cash outflow outlook to less than $16 million, down from less than $18 million[12] - Total cash and short-term investments were $31.7 million, with gross debt at $12.1 million at the end of Q3 2024[4] - Cash used in operating activities for the nine months ended September 30, 2024, was $11,455 thousand, a decrease from $15,922 thousand for the same period in 2023, reflecting a reduction of approximately 28.9%[29] - The company’s cash and cash equivalents decreased to $6,145 thousand as of September 30, 2024, down from $32,112 thousand at the end of the previous year, a decline of approximately 81.9%[27] - Free cash flow for the nine months ended September 30, 2024, was $(12,013) thousand, an improvement from $(23,544) thousand for the same period in 2023, indicating a reduction of approximately 48.9%[29] Expenses and Liabilities - Operating expenses decreased to $7.5 million in Q3 2024 from $10.2 million in Q3 2023, driven by reduced headcount and spending[8] - Total current liabilities increased to $9,719 thousand as of September 30, 2024, compared to $8,875 thousand as of December 31, 2023, representing an increase of approximately 9.5%[26] - The company’s long-term debt decreased to $10,857 thousand as of September 30, 2024, down from $13,251 thousand as of December 31, 2023, representing a decline of approximately 18.1%[26] Asset Management - As of September 30, 2024, total assets decreased to $124,099 thousand from $128,587 thousand as of December 31, 2023, representing a decline of approximately 3.9%[26] - The company recorded $2.8 million in non-recurring, non-cash charges related to inventory disposal, which impacted gross profit[4][7] - The company’s accumulated deficit increased to $(112,812) thousand as of September 30, 2024, compared to $(91,786) thousand as of December 31, 2023, indicating a worsening of approximately 22.9%[26] Financing Activities - The company raised $15,141 thousand from equity financing in the three months ended September 30, 2024, compared to $22,915 thousand in the same period of 2023, a decrease of approximately 34.1%[27] - Adjusted EBITDA for the three months ended September 30, 2024, was $(5,001) thousand, an improvement from $(5,477) thousand for the same period in 2023, reflecting a positive change of approximately 8.7%[28] - The company reported a net loss of $7,565 thousand for the three months ended September 30, 2024, compared to a net loss of $10,153 thousand for the same period in 2023, indicating an improvement of approximately 25.9%[28]

Core Viewpoint - Alpha Teknova, Inc. is set to report its financial results for Q3 2024 on November 7, 2024, and will host a webcast and conference call for investors [1] Group 1: Company Overview - Teknova has been innovating in the manufacture of critical reagents since 1996, focusing on accelerating the discovery and development of novel therapies [2] - The company provides customizable solutions for various stages of the workflow, supporting sectors such as cell and gene therapy, molecular diagnostics, and synthetic biology [2] - Teknova operates from a headquarters in Hollister, California, with over 200,000 square feet of advanced facilities designed for efficient production [2] Group 2: Financial Reporting - The financial results for the third quarter ended September 30, 2024, will be reported after market close on November 7, 2024 [1] - A live webcast and conference call will take place on the same day at 5:30 p.m. Eastern Time, with a replay available approximately two hours after the event [1]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Core Viewpoint - Alpha Teknova, Inc. has announced a definitive agreement for a private placement of 12,385,883 shares of common stock at a price of $1.24 per share, aiming to raise approximately $15.4 million before expenses [1][7]. Company Overview - Teknova is a leading producer of critical reagents for the life sciences industry, focusing on the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics [1][4]. - The company has been innovating since 1996 and offers customizable solutions for various stages of the workflow, supporting sectors such as cell and gene therapy, molecular diagnostics, and synthetic biology [4]. Financial Details - The private placement is expected to close on or about July 12, 2024, subject to customary closing conditions [7]. - The gross proceeds from the private placement are anticipated to be approximately $15.4 million, which will be used for general corporate purposes [7]. Regulatory Compliance - The securities in the private placement are not registered under the Securities Act and may not be reoffered or resold in the U.S. without an effective registration statement or applicable exemption [3][8]. - Teknova has agreed to file an initial registration statement with the SEC covering the resale of the securities within 45 days of the definitive agreement [8].

A downtrend has been apparent in Alpha Teknova (TKNO) lately with too much selling pressure. The stock has declined 24.6% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversol ...

Investors might want to bet on Alpha Teknova (TKNO) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The p ...

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President and Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Steven Mah - TD Cowen Matt Larew - William Blair Vidyun Bais - BTIG Operator Good day and thank you for standing by. Welcome to Teknova's First Quarter 2024 Financial Results Conference Call. At ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40538 ALPHA TEKNOVA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Corporate and Financial Updates 1 Exhibit 99.1 Teknova Reports First Quarter 2024 Financial Results First quarter 2024 total revenue was $9.3 million, up 2% from prior year Launch of Build-TekTM Custom Configurator Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13, 2024 – Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular di ...